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Conclusions. Accelerated breast hypofractionation treatment allows minimizing the impact of radiation therapy on the patients
quality of life without worsening tolerance and cosmetic results. Its application, however, requires a quality improvement of the
treatments compared to the conventional procedure.
http://dx.doi.org/10.1016/j.rpor.2013.03.073
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Purpose. Show our experience in accelerated partial breast irradiation (APBI) with HDR brachytherapy, implementation and one
year of treatment, in a selected group of patients with early-stage breast cancer.
Methods and materials. From August 2011 to November 2012, six selected patients with T1 N0, Grade 1–2 ductal breast cancer,
were treated after breast-conserving surgery, with high-dose-rate (HDR) multicatheter brachytherapy. Inclusion criteria were the
most restrictive of ASTRO and ESTRO recommendations. In all cases we performed a CT scan, in which we perform a virtual
dosimetry preimplantation subsequently reproduce the ﬁnal implant. The clinical target volume was drawn with a 1-cm margin
around the surgical clips or seroma, protecting skin and chest wall. All the regions of interest were contoured according to the
International Commission on Radiation Units and Measurements reports 50 and 62 recommendations. Prescribed dose to the
PTV was 34Gy in 3.4Gy fractions in 5 days.
Results. The average size of the PTV was 63.7 cc (50–120), with V100% mean 94.5% V150% mean 26.94 cc, V200% mean 10.69 cc and
D90 average was 105%. DHI (Dosie Homogenity Index) average was 0.62, and COIN (Conformatin Index) average was 0.66. Acute
toxicity: pain in 2 patient, and hematoma in 2 patients. Acute Radiodermitis was not observed. Late toxicity: ﬁbrosis grade1
was observed in 2 patients, and grade 2 in another patient. Slight pigmentation is observed in 2 patients. There have been no
locoregional recurrences or metastases. The aesthetic result was good or very good en 5 patients, and excellent in one.
http://dx.doi.org/10.1016/j.rpor.2013.03.074
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Introduction. Previous studies have demonstrated increased cardiac mortality and morbidity after left-sided breast irradiation.
Different technologies have been developed to minimize this problem. We have analyzed the dosimetry and dose-volume his-
tograms of ten patients diagnosedwith left side breast cancer, stage IA and IB; forwhomweplanned the same two-ﬁeld tangential
treatment with and without active breathing control (ABC) technique.
Objective. To demonstrate dose reduction to left anterior descending coronary artery (LAD) and heart using moderate deep
inspiration breath hold (mDIBH) with ABC.
Methods. Patients underwent scanning free breathing (FB) and then employing active breathing control technique. The mDIBH
treatments were compared with the standard free-breathing for each patient. Dosimetric parameters evaluated: mean heart
dose, heart V50%, mean LAD dose, maximal dose to 0.2 cm3 of the LAD, mean left lung dose and percentage of lung receiving
≥20Gy.Results. The heart V50 decreased to 0% in 8 of 10, the decreasing average was 95%, from a 1.58% of the heart receiving
more than 50Gy in the FB plan to a media of 0.08% with mDIBH (p:0.012); overall, the mean dose to the heart was reduced from
1.989Gy to 0.98Gy (p:0.005), a relative reduction of 50.4%. The mean dose to the LAD was reduced from 14.06Gy with FB to 3.55Gy
using mDIBH (p:0.008), relative reduction of 74.75%. The maximal dose to 0.2 cm3 was reduced from 21.69Gy to 6.36Gy, (p: 0.008),
a reduction of 70.67%. Regarding the left lung, this technique does not seem to show a clear improvement, nor in the V20, nor
in the mean dose.Conclusion. MDIBH with ABC signiﬁcantly reduces heart and LADC doses, what can potentially reduce cardiac
risks. However, lung doses do not show a homogeneous decrease.
http://dx.doi.org/10.1016/j.rpor.2013.03.075
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Introduction. Coronary artery disease is the leading cause of mortality among RT-treated survivors of breast cancer. Signiﬁcantly
increases the risk of 2–3 times compared to the untreated population. The median time to onset varies between 6 and 10 years
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(range: 5–20). In 75% of symptomatic patients catheterization, have been described 90–100% stenosis of at least one artery. The
anterior descending branch was affected in 70% of such patients.
Objetives. The heart is an organ at risk incorrectly deﬁned today as a solid organ. Since it is the anterior wall of the VI which
receive 50% or more of the dose, we think the proper contouring of the left coronary artery and its branches, as well as the
left ventricular wall, embryological, histological, anatomical and functionally compromised structures that should be taken into
account when a correct delimitation it is done, key aspect in reducing the long-term cardiac events produced in breast cancer
patients treated with radiotherapy.
Methods.We brieﬂy reviewall aspects of normal left ventricular structure and Standardizedmyocardial segmentation andnomen-
clature for tomographic imaging of the heart of American Heart Association. We outline the whole heart (A), the heart with its
four chambers (B), only the left ventricle (C) and anterior descending coronary artery in ﬁve women, which had been made a CT
with IV contrast for radiotherapy planning of esophageal carcinoma. We compared the maximum, minimum, mean dose, Vx.
Results. All doses vary signiﬁcantly if we outline in the ways previously mentioned, being the most anatomically correct LV
sole contouring although dose unfavorable. With the delineation of anterior descending coronary proximal, middle and distal,
maximum, mean and minimum doses were similar. The anterior descending coronary 65% of its length receives more than 50%
of the dose.
Conclusions. The correct contouring should be limited to cardiac anterior wall of the left ventricle and the coronary artery, the
conformation of the ﬁelds, the techniquewill be oriented to themaximumpreservation of these two structures. Note the probably
damage of cardiac stem cells source at epicardium, and therefore the possible regenerative cell therapy for myocardial injury
and the formation coronary vessels.
http://dx.doi.org/10.1016/j.rpor.2013.03.076
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Introduction. Standard fractionation RT is widely used for breast cancer treatments. Nevertheless, the same level of efﬁcacy and
security has been demonstrated with altered fractionations in terms of local control and toxicity rates. Goals: Evaluation of acute
tolerance, late effects, and efﬁcacy of hypofractionated treatments on breast cancer patients.
Material and methods. From February 2012, seventeen breast cancer patients staged pT1-T2, N0-1, M0 have received 3D planned
adjuvant radiotherapy with a fractionation schedule of 15 fractions of 2.67Gy up to a total dose of 40Gy during three weeks after
tumorectomy, sentinel node biopsy or axillary node dissection (2 patients). Two patients received a boost on the surgical bed
subsequently. Weekly consultations during treatment have been performed in order to evaluate treatment tolerance.
Results. Mean age was 67.5 y.o. (50–84). Stage distribution was 68.7% stage I and 31.7% stage II. Most patients had Inﬁltrating
Ductal Carcinoma (75%), followed by Inﬁltrating Lobular Carcinoma (18,7%) and Mucinous Carcinoma (6,2%). Histologic grade
was % Grade I (56.2%), Grade II (37.5%) or Grade III (6.2%). Two patients received adjuvant chemotherapy whereas the whole
group has received hormonal treatments. Cutaneous toxicity, graded with RTOG scale, grade 1 (43.7%), and grade 2 (12.5%). No
grade 3 radiodermatitis has been observed.
Conclusion. Hypofractionated adjuvant breast irradiation allows the shortage of the radiotherapy course without an increment in
the cutaneous toxicity burden. The study is progressing in order to asses the local control rates and late effects.
http://dx.doi.org/10.1016/j.rpor.2013.03.077
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Introduction. In February 2012 the project LIFE (INNPRONTA) is approved by the Council ofMinisters at the request of the CDTI. This
program represents a qualitative leap in R & D collaboration between ﬁrms and research organizations. Companies participating
in the LIFE project are: ERESA (consortium leader), Genome Systems, Gem-Imaging, IUCT, Instituto Cartuja, Proton Bilbomática
and Laser Applications.
